| Industry | 制造业 | ||||||||||||||||||||||||
| Company Introduction | 深圳信立泰药业股份有限公司（以下简称“信立泰”）成立于1998年，2009年在深交所上市（股票代码：002294），是一家立足中国、面向全球、研产销一体化的创新驱动型医药企业。信立泰坚守“为人类健康提供卓越的医药产品”的神圣使命，以优质创新产品和循证医学推广为核心竞争力，努力打造成为以心脑血管为主的慢病领域龙头企业。 信立泰先后承担“十一五”“十二五”“十三五”国家重大专项及国家、省、市的重大科技项目60余项，3次获“中国专利金奖”，荣获“国家技术创新示范企业”“中国医药研发产品线最佳工业企业”等荣誉。 | ||||||||||||||||||||||||
| Main Business | 药品、医疗器械产品的研发、生产、销售。 | ||||||||||||||||||||||||
| Legal Representative | 叶宇翔 | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | 杨健锋 | ||||||||||||||||||||||||
| Solicitors | 北京市金杜律师事务所 | ||||||||||||||||||||||||
| Auditors | 大信会计师事务所（特殊普通合伙） | ||||||||||||||||||||||||
| Tel No | 0755-83867888 | ||||||||||||||||||||||||
| Fax No | 0755-83867338 | ||||||||||||||||||||||||
| Website | www.salubris.com | ||||||||||||||||||||||||
| investor@salubris.cn | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 10/09/2009 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ 0.520 | ||||||||||||||||||||||||
| DPS(RMB)* | ¥ 0.500 | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 7.193 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 32.256B |
 |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |